Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716]
Corresponding Author of This Article
Dr. David E Bernstein, MD, Chief of Division of Hepatology, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. dbernste@nshs.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Nov 28, 2015; 7(27): 2716-2728 Published online Nov 28, 2015. doi: 10.4254/wjh.v7.i27.2716
Hepatic manifestations of non-steroidal inflammatory bowel disease therapy
Robert Hirten, Keith Sultan, Ashby Thomas, David E Bernstein
Robert Hirten, Keith Sultan, Ashby Thomas, David E Bernstein, Division of Gastroenterology, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States
David E Bernstein, Division of Hepatology, North Shore University Hospital-Long Island Jewish Medical Center, Manhasset, NY 11030, United States
Author contributions: Hirten R, Sultan K and Bernstein DE contributed to conception and design; Hirten R, Sultan K and Thomas A contributed to drafting of the article; Hirten R, Sultan K, Thomas A and Bernstein DE contributed to critical revision of the article for important intellectual content; Hirten R, Sultan K, Thomas A and Bernstein DE contributed to final approval of the article.
Conflict-of-interest statement: The authors declare that no conflicts of interest exist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. David E Bernstein, MD, Chief of Division of Hepatology, North Shore University Hospital-Long Island Jewish Medical Center, 300 Community Drive, Manhasset, NY 11030, United States. dbernste@nshs.edu
Telephone: +1-516-5624664 Fax: +1-516-5621688
Received: June 28, 2015 Peer-review started: June 29, 2015 First decision: July 28, 2015 Revised: October 25, 2015 Accepted: November 13, 2015 Article in press: November 17, 2015 Published online: November 28, 2015 Processing time: 152 Days and 14.9 Hours
Abstract
Inflammatory bowel disease (IBD) is composed of Crohn’s disease and ulcerative colitis and is manifested by both bowel-related and extraintestinal manifestations. Recently the number of therapeutic options available to treat IBD has dramatically increased, with each new medication having its own mechanism of action and side effect profile. A complete understanding of the hepatotoxicity of these medications is important in order to distinguish these complications from the hepatic manifestations of IBD. This review seeks to evaluate the hepatobiliary complications of non-steroid based IBD medications and aide providers in the recognition and management of these side-effects.
Core tip: Recently the number of medical therapies for inflammatory bowel disease (IBD) has greatly increased. Each medication has its own mechanism of action and side effect profile. This review article discusses the hepatic side effects of medications used to treat IBD enabling physicians to better recognize and manage these complications.
